51. The effect of NSAIDs and COX-2 specific inhibitor on Helicobacter pylori-induced PGE[sub2] and HGF in human gastric fibroblasts.
- Author
-
Takahashi, M., Katayama, Y., Takada, H., Kuwayama, H., and Terano, A.
- Subjects
HELICOBACTER pylori ,GASTROINTESTINAL diseases ,ULCERS ,HEPATOCYTE growth factor ,FIBROBLASTS ,DRUGS - Abstract
There is compelling evidence for the pivotal role of Helicobacter pylori in the pathogenesis of gastrointestinal ulcer disease. However, despite the bacterium’s toxicity, the majority of H. pylori infections are not accompanied by gastric ulcers. This implies the existence of a host mechanism offsetting H. pylori toxicity. To evaluate gastric fibroblasts’ expression of hepatocyte growth factor (HGF), which is known to facilitate gastric ulcer healing, in the presence of H. pylori; to compare the effect on H. pyloriinduced HGF expression of a COX2 selective inhibitor with that of nonselective nonsteroidal antiinflammatory drugs (NSAIDs).Human gastric fibroblasts were cultured from human gastric mucosa obtained at surgery. Prostaglandin E[sub2] (PGE[sub2]) and HGF were measured by EIA. The expression of COX2 mRNA was assessed by the TaqMan quantitative RTPCR system. H. pylori increased PGE[sub2] release in gastric fibroblasts. H. pylori induced expression of COX2 mRNA, which indicates that PG induction by H. pylori is through COX2. Sulindac sulphide, etodolac and NS 398 all inhibited H. pyloriinduced PGE[sub2] release to the same extent. These agents also inhibited H. pylori induced HGF release. Gastric flbroblasts produce PG and HGF in response to the presence of H. pylori, which may be considered part of the human body’s defensive reaction to H. pylori toxicity. This defensive mechanism is inhibited not only by COX2 nonselective NSAIDs but also by a COX2 selective inhibitor. These findings indicate the importance of COX2 in chronic H. pylori infection. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF